AdAlta Ltd. · ASX:1AD
AdAlta — 4th BioCentury-BayHelix East-West Biopharma Summit 2025
18 slides from AdAlta's conference presentation, Mar 4, 2025
Slide 1: AdAlta to present at 4th BioCentury-BayHelix East-West Biopharma Summit
ASX Announcement | 4 March 2025 AdAlta Limited (ASX:1AD) AdAlta to present at 4th BioCentury-BayHelix East-West Biopharma Summit AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next generation cell and protein therapeutic products is presenting at the 4th BioCentury-BayHelix East-
Slide 2: For personal use only
AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model delivering a rapid return on investment in each project that is replicable and provi
Slide 3: Commercialising Cellular Immunotherapies East to West
For personal use only COMMERCIALISING CELLULAR IMMUNOTHERAPIES “EAST TO WEST” ADALTA LIMITED (ASX:1AD) | INVESTOR PRESENTATION | FEBRUARY 2025 AdAlta Limited (ASX:1AD) | Investor Presentation | February 2025 | 1
Slide 4: Important Notice & Disclaimer
IMPORTANT NOTICE & DISCLAIMER Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. For personal use only This presentation is
Slide 5: Developing Next Generation Cell and Protein Therapeutics
DEVELOPING NEXT GENERATION CELL AND PROTEIN THERAPEUTICS AdAlta Limited For personal use only Code ASX:1AD Specialist in next-generation cell and protein therapeutics for fatal diseases Market Capitalisation $11.0m Enterprise Value $9.4m First three term sheets signed of "East-to- Cash $1.6m West" c
Slide 6: East to West Strategy Central to AdAlta's Growth
For personal use only “EAST TO WEST” STRATEGY CENTRAL TO ADALTA’S GROWTH AdAlta Limited (ASX:1AD) | Investor Presentation | February 2025 | 44
Slide 7: Rationale for Our Strategy
RATIONALE FOR OUR STRATEGY Market Opportunity Competitive Advantage First Assets For personal use only Cancers that are solid • Networks: Asia's rich innovation, Initial three assets under term sheet from tumours and remain Australia's clinical and manufacturing pipeline of 10 high-potential therapi
Slide 8: East to West Strategy Overview
“EAST TO WEST” STRATEGY OVERVIEW Substantial value inflection potential by bringing “Eastern” cellular For personal use only immunotherapy innovations to “Western” regulated markets AdAlta has clear aspirational growth targets for its Combining Asia's innovative T cell therapies for solid cancers an
Slide 9: Becoming a Valuation Multiplier for Asian Partners
BECOMING A VALUATION MULTIPLIER FOR ASIAN PARTNERS For personal use only 3 In-license market leading 3 assets from Asia (“East”): 1 Low acquisition cost. By financing to next inflection On-licensing: point AdAlta acquires a Establish global share of the asset at exit manufacturing network and on-lic
Slide 10: Progress and Potential
PROGRESS AND POTENTIAL Australian clinical trial data facilitates We are here pivotal studies, For personal use only today licensing agreements First IND and asset sales approval (F) Three high value First technology assets secured (F) Three in-licensing transfer to 2028+ term sheets commence (F) “E
Slide 11: Three Assets Under Exclusive Due Diligence
THREE ASSETS UNDER EXCLUSIVE DUE DILIGENCE First in-licensing term sheet Second in-licensing term sheet Third in-licensing term sheet For personal use only Lung, mesothelioma, ovarian, cervical, Endothelial solid cancers incl. colorectal, Target cancer markets Gastric, gynaecological and epithelial
Slide 12: AD-214: A New Approach to Fibrosis, Available for Partnering
For personal use only AD-214: A NEW APPROACH TO FIBROSIS AVAILABLE FOR PARTNERING AdAlta Limited (ASX:1AD) | Investor Presentation | February 2025 | 10 10
Slide 13: Monetising Fibrosis Disease Drug Candidate AD-214
MONETISING FIBROSIS DISEASE DRUG CANDIDATE AD-214 Investment to date has built strong value proposition Key Priority: Seek out-licensing or third-party investment to For personal use only unlock next level of value First in class molecule targeting established mode ✓ Competitively positioned as only
Slide 14: Pharma Companies Value IPF/Fibrosis Assets
PHARMA COMPANIES VALUE IPF/FIBROSIS ASSETS Upfront payment to Contingent Clinical Phase at Date Licensor/target Licensee/acquirer Transaction licensor milestones transaction For personal use only Aug-22 License US$100m US$600m 2 complete Apr-20 Acquisition US$45m Not disclosed 2a complete Nov-19 Acq
Slide 15: Team and Investment Proposition
For personal use only TEAM AND INVESTMENT PROPOSITION AdAlta Limited (ASX:1AD) | Investor Presentation | February 2025 | 13 13
Slide 16: Experienced Team with Global Reach
EXPERIENCED TEAM WITH GLOBAL REACH Board Executive “East-to-West” Strategy AD-214: Fibrosis For personal use only Paul MacLeman, DVM Angus Tester, PhD Kevin Lynch TBA - engaged Chair Senior Manager, Consultant CMO Consultant CMO Projects and Programs Tim Oldham, PhD Prof Andrew Wilks Joseph Tyler CE
Slide 17: Transaction-Based Growth Strategy Is Being Delivered
TRANSACTION-BASED GROWTH STRATEGY IS BEING DELIVERED For personal use only “East to West” cellular The first three assets under Experienced team and accessible immunotherapy growth strategy exclusive due diligence for the “East global network ready to execute a leveraging regional and business to We
Slide 18: For More Information Please Contact
For personal use only FOR MORE INFORMATION PLEASE CONTACT: TIM OLDHAM CEO & MANAGING DIRECTOR +61 403 446 665 [email protected] INVESTOR RELATIONS THE CAPITAL NETWORK JULIA MAGUIRE +61 2 7257 7338 [email protected] WWW.ADALTA.COM.AU AdAlta Limited (ASX:1AD) | Investor Presentation
AdAlta — 4th BioCentury-BayHelix East-West Biopharma Summit 2025 on 6ix